The Blue House “Speaking for 27 minutes with President Bansel on the night of the 28th”
Secured twice as much as the original government negotiations
President Moon Jae-in is presiding over an emergency inspection meeting of the corona 19 metropolitan area quarantine situation held at the Blue House National Crisis Management Center on the 9th. yunhap news
The Blue House announced that it has secured 20 million COVID-19 vaccines through the US pharmaceutical company Modena. Spokesman Kang Min-seok said on the 29th, “President Moon Jae-in made a video call with Stefan Vanssel Modena Shiio (CEO, CEO) from 9:53 to 10:20 last night. During the 27-minute call, Bancel Modena and Siio decided to supply 40 million doses of 20 million people to Korea.” This is twice the amount of 20 million doses the government and Modena were negotiating. The Blue House said it is also favorably changing the domestic supply conditions of the vaccine. Spokesman Kang said, “The purchase price (per dose) will be lowered,” he said. “We decided to accelerate the vaccine supply period. We initially decided to supply it in the 3rd and 4th quarters of next year, but we decided to make additional efforts to bring the timing further to the 2nd and 4th quarters.” Modena’s reaction was also positive. Spokesman Kang said, “We will do our best to ensure that the supply is delivered early. “If you want to sign a contract quickly, you can do it within this year,” he said. President Moon told Bancel Siio, “This is news of hope for the Korean people. “Let’s sign a contract within the year as much as possible,” he said. The Blue House explained that if the contract with Modena is concluded, Korea will secure 56 million worth of Corona 19 vaccine. President Moon and Bancel Siio also joined forces in vaccine development. It has decided to cooperate with domestic research institutes for clinical trials of vaccine candidates, while strengthening cooperation for consignment production of modders and vaccines by Korean companies. “If we cooperate with Korea, we can shorten the time required to develop a corona vaccine even more. We are well aware that large Korean companies have strong production capacity. The vaccine production capacity was insufficient, but large-scale production is possible during consignment production (Korea),” said the Blue House. By Lee Wan, staff reporter [email protected]